A fixed-dose combination ophthalmic solution containing a non-steroidal anti-inflammatory drug (NSAID) and a selective histamine H1-receptor antagonist. It provides dual-action therapy for allergic conjunctivitis by inhibiting prostaglandin synthesis (anti-inflammatory) and blocking histamine release (anti-allergic). It is a mainstay for moderate to severe allergic eye conditions in the Indian market.
Adult: One drop instilled into the affected eye(s) twice daily (every 8-12 hours).
Note: 1. Wash hands. 2. Tilt head back. 3. Gently pull lower eyelid to form a pouch. 4. Instill one drop without touching the dropper tip to eye or any surface. 5. Close eyes gently for 1-2 minutes, applying gentle pressure to the nasolacrimal duct (inner corner of eye) to minimize systemic absorption. 6. Wait at least 10 minutes before inserting contact lenses. 7. Wait at least 5 minutes before instilling any other eye drop.
Provides synergistic action for allergic conjunctivitis. Olopatadine is a relatively selective H1-receptor antagonist and inhibits the release of histamine and other inflammatory mediators (like tryptase, prostaglandin D2, leukotrienes) from mast cells. Ketorolac tromethamine is a potent NSAID that inhibits the enzyme cyclooxygenase (COX), thereby reducing the synthesis of prostaglandins, which are key mediators of ocular inflammation, pain, and photophobia.
Pregnancy: Category C (US FDA). Animal studies show risk. Adequate human studies lacking. Use only if potential benefit justifies potential fetal risk, especially in third trimester (risk of premature ductus arteriosus closure). Avoid in late pregnancy.
Driving: May cause transient blurred vision. Patients should not drive or operate machinery until vision clears.
| Oral NSAIDs (e.g., Ibuprofen, Diclofenac, Aspirin) | Increased risk of systemic NSAID adverse effects (GI bleeding, renal impairment). | Moderate |
| Anticoagulants (e.g., Warfarin) | Potential increased risk of bleeding due to antiplatelet effect of Ketorolac. | Moderate |
| Corticosteroids (oral or topical) | Increased risk of GI ulceration and impaired corneal healing. | Moderate |
| ACE Inhibitors (e.g., Enalapril) / ARBs (e.g., Telmisartan) | Reduced antihypertensive effect; risk of renal function deterioration. | Moderate |
| Diuretics (e.g., Furosemide) | Risk of nephrotoxicity and reduced diuretic efficacy. | Moderate |
| Methotrexate | Increased methotrexate toxicity due to reduced renal clearance. | Major |
| Other topical ophthalmic NSAIDs | Additive risk of corneal adverse effects. Avoid concomitant use. | Major |
Same composition (Ketorolac (0.4% w/v) + Olopatadine (0.1% w/v)), different brands: